Please assess the completion status of the following clinical trial:

Trial Title: Effects Of Exenatide On Liver Biochemistry, Liver Histology And Lipid Metabolism In Patients With Fatty Liver Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age \>18 years, \< 70 years, inclusive~* Type 2 diabetes on stable doses of sulfonylurea and/or metformin~* Body mass index \> 35 kg/m2~* Presumed diagnosis of NAFLD based upon~* an ALT \> 1.5 times the upper limit of reference range,~* no evidence of other causes of liver disease and~* ultrasound findings compatible with fatty liver~Exclusion Criteria:~* Clinical signs of cirrhosis as evidenced by any of the following~* spider angiomata,~* splenomegaly,~* ascites~* jaundice~* encephalopathy~* INR \> 1.2~* Platelet count \< 100,000/ml~* Serum albumin \< 3.0 g/dL~* Other liver disease including chronic viral hepatitis (B or C), alcohol abuse, hemochromatosis, alpha-1 antitrypsin deficiency, autoimmune hepatitis, Wilson's disease, primary sclerosing cholangitis or primary biliary cirrhosis.~* Current use of \> 20 g of alcohol per day or unwillingness to avoid alcohol during the course of the study~* Treatment with a thiazolidinedione or exenatide within 6 months of enrolling in the study~* AST or ALT \> 10 times the upper limit of normal~* Treatment with any investigational drug within 4 weeks of enrollment~* Pre-menopausal, fertile women unwilling to use contraceptives during the study period.~* Pregnancy or lactation~* Initiation or change in dose of hypolipidemic drugs (statins, niacin, cholestyramine are allowed) within 6 months of enrollment~* Use of anticoagulation, bleeding disorders or other contraindications to liver biopsy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Exenatide (Type: EXPERIMENTAL): exenatide 5 µg BID s.c. daily for 28 days, followed by 10 µg BID s.c. daily from day 29 to week 24

Based on this trial design, predict the completion outcome and termination type (if applicable).